Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio (Nasdaq: PASG) announced FDA clearance for its PBGM01 gene therapy, targeting infantile GM1 gangliosidosis, marking a significant milestone. The global Phase 1/2 clinical trial, named Imagine-1, is set to dose its first patient in Q1 2021. GM1 is a rare CNS disorder affecting infants, with no approved therapies. The trial will enroll 8 patients across 4 cohorts to evaluate safety and biomarker data. PBGM01 aims to restore enzyme activity to mitigate neurodegeneration. The company has also obtained UK regulatory approval for the treatment.
Passage Bio (Nasdaq: PASG) announces a long-term lease for a new CMC laboratory at the Princeton West Innovation Campus in Hopewell, NJ, expected to open in Q2 2021. This facility aims to enhance internal manufacturing capabilities for gene therapy programs. The lab will focus on analytical capabilities, clinical assay development, and product testing, complementing a recently opened CGMP suite at Catalent. The expansion supports the company's strategy to advance its gene therapy pipeline, with plans to hire over 20 new positions in 2021.
Passage Bio has received approval from the UK’s Medicines Healthcare Products Regulatory Agency (MHRA) for the Clinical Trial Authorization (CTA) of its lead gene therapy candidate, PBGM01, aimed at treating GM1 gangliosidosis, a rare and life-threatening CNS disorder. This marks the initiation of the global PBGM01 clinical trial program, with patient enrollment in the UK expected to begin in Q2 2021. The Phase 1/2 trial will explore safety and efficacy through a single injection in pediatric patients and aims to report initial results by mid-2021.
Passage Bio has announced the commencement of manufacturing operations for its gene therapy product candidates following the completion of a dedicated Current Good Manufacturing Practice (CGMP) suite at Catalent's facility in Maryland. This marks a significant milestone in advancing therapies for rare monogenic CNS disorders, enabling better supply chain control and scalability. The partnership with Catalent allows for efficient production and distribution, enhancing the potential for clinical and commercial success.
Passage Bio (Nasdaq: PASG) announces that CEO Bruce Goldsmith will participate in a fireside chat at the Piper Sandler 32nd Annual Healthcare Conference from December 1 to 3, 2020. This virtual event enables registered attendees to view the chat on-demand. A recording will be accessible for 30 days on the company's Investors & Media webpage. Passage Bio focuses on developing gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania’s Gene Therapy Program to enhance its research and clinical pipeline.
Passage Bio has secured rights to innovative technology from the University of Pennsylvania’s Gene Therapy Program aimed at mitigating dorsal root ganglia (DRG) toxicity observed in gene therapy. This collaboration could enhance the safety of its gene therapy treatments for rare CNS disorders. Although safety studies have not indicated clinical manifestations of DRG toxicity, Passage Bio expresses optimism about integrating this new approach into its programs if it proves beneficial. The company anticipates initiating clinical trials for several programs in 2021.
Passage Bio (Nasdaq: PASG), a company specializing in genetic therapies for rare CNS disorders, will participate in two virtual investor conferences in November. The Guggenheim Virtual Healthcare Talks will take place on November 16, 2020, followed by the Stifel Virtual Healthcare Conference on November 18, 2020, where Passage Bio will present at 4:00 p.m. ET. The company is committed to developing innovative gene therapies in collaboration with the University of Pennsylvania's Gene Therapy Program.
Passage Bio (NASDAQ: PASG) reported its third-quarter financial results as of September 30, 2020, showing cash equivalents of $335.7 million, up from $158.9 million in December 2019. The company is advancing three Phase 1/2 clinical trials for GM1, FTD-GRN, and Krabbe disease, with the first patient dosing for PBGM01 expected in Q1 2021 and safety data anticipated mid-2021. Additionally, PBGM01 received Orphan Drug Designation from the European Commission. R&D expenses surged to $20.8 million, while the net loss reached $28.5 million, or $0.63 per share, reflecting increased operational investments.
Passage Bio (NASDAQ: PASG) partners with Invitae to enhance genetic testing for GM1 gangliosidosis. This collaboration offers free genetic testing and counseling through Invitae’s Detect LSDs program, promoting early diagnosis and access to clinical trials. The initiative aims to support patients, especially infants, as GM1's severe form has a life expectancy of only 2-4 years. Passage Bio plans to initiate its Phase 1/2 trial for PBGM01 shortly, positioning the partnership as crucial for early intervention and treatment.
Passage Bio (NASDAQ: PASG) announced a conference call and live webcast scheduled for 8:30 a.m. ET on November 10, 2020, to discuss its Q3 2020 financial results and recent business highlights. The call can be accessed by dialing 833-528-0605 (domestic) or 830-221-9711 (international) with conference ID 8478507. The archived webcast will be available for 30 days post-event. The company focuses on gene therapies for rare CNS disorders and collaborates with the University of Pennsylvania’s Gene Therapy Program.